Moscow has increased the production of innovative medicines

Moscow holds a leading position in the country in terms of the pharmaceutical industry and the number of medicines being marketed. In 11 months of 2025, the production of drugs increased by 11.8% compared to the same period in 2024, said the mayor of the capital, Sergei Sobyanin, in the MAX channel.

Special attention is being paid to biopharmaceuticals, Sobyanin noted. "This direction opens up new possibilities for the treatment of complex diseases, from oncological and autoimmune pathologies to rare genetic disorders," wrote the mayor of Moscow.

For example, Technopolis Moscow, a resident of the SEZ, produces biologics used for orphan as well as socially significant diseases. For example, a biosimilar of the thrombolytic drug alteplaza, used in acute myocardial infarction and ischemic stroke, Sobyanin said. Another technopolis resident company creates medicines for the treatment of breast cancer, colorectal cancer, non-Hodgkin's lymphoma and rheumatoid arthritis.

Another factory in the capital is expected to present its first monoclonal antibody—based drug, adalimumab, a biological immunosuppressant. It is used for more than 10 medical conditions, in particular, rheumatoid arthritis, Crohn's disease, Behcet's disease and others.

One of the largest pharmaceutical clusters in the country has been created at the Alabushevo and Pechatniki SEZ Technopolis Moscow sites. It unites 14 developers and manufacturers of medicines who are residents of the Moscow special economic zone and receive a number of tax preferences.

In total, Technopolis Moscow SEZ has more than 2 million square meters. m of high-tech industrial and public-business infrastructure. There are more than 240 companies operating here, the number of jobs in which exceeds 30 thousand.

All important news is on the Izvestia channel in the MAX messenger.